Abstract: PD05-07
Sources of Funding: NONE

Introduction

Chronic prostatitis/Chronic pelvic pain syndrome (CP/CPPS) is a common urological problem of young males. Alpha blockers, antibiotics and analgesics are commonly used drugs for CP/CPPS but there are no treatment guidelines available. We evaluated the effectiveness of PDE5-inhibitors in CP/CPPS.

Methods

Total of 68 patients were randomized into two groups. Group A (n=32) received alfuzosin and levofloxacin (standard treatment) whereas group B (n= 36 ) received tadalafil 5mg (PDE 5 inhibitor) in addition to alfuzosin and levofloxacin for 6weeks.The groups were analyzed pre and post treatment with National Health Institute Chronic Prostatitis Symptom Index (NIH-CPSI), International Index of Erectile Function ( IIEF-5), International Prostate Symptom Score(IPSS), scores and uroflowmetry.

Results

Changes observed in the NIH-CPSI of group B at six weeks were greater than those at baseline (group A, ?8.4 vs. group B, ?18.0; p<0.05). The mean change in total IPSS from baseline was higher in group B than that in group A (group A, ?3.4 vs. group B, ?8.8; p <0.05). Change in IPSS-QOL index from baseline was significant in Group B (group A, -0.63 vs. group B,-2.03 ; p<0.05). Group B showed a significantly greater increase in the IIEF-EF score than group A (group A -0.7 vs. group B +6.4; p<0.05). Qmax pre and post therapy showed significant improvement in group B when adjusted for age (group A, -2.9 vs group B, +2.56; p<0.05).

Conclusions

PDE-5 inhibitor results in significant improvement in CP/CPPS symptoms and quality of life and is well tolerated.

Funding

NONE